Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

This trial is studying a medication called vericiguat in people who are hospitalized with a serious worsening of heart failure — a condition where the heart cannot pump blood well enough to meet the body's needs. Researchers want to learn if adding vericiguat to standard heart failure medications improves outcomes. **You may be eligible if:** - You have been diagnosed with decompensated heart failure (meaning your heart failure has recently gotten worse) - Your heart's pumping function (ejection fraction) is 45% or less - You have moderate to severe symptoms (NYHA class III–IV or worsening class II) - Your blood levels of a heart stress marker (NT-proBNP) are elevated **You may NOT be eligible if:** - Your blood pressure is below 100 mmHg - You are currently taking or plan to take long-acting nitrates, certain blood pressure drugs (PDE5 inhibitors like sildenafil), or other drugs that relax blood vessels in a similar way - You require IV medications to support your heart or have a mechanical heart pump implanted Talk to your doctor to see if this trial is right for you.